Association between tumor mutational burden (TMB) and mutational profile and its effect on overall survival: A post hoc analysis of patients with TMB-high and TMB-low metastatic cancer treated with immune checkpoint inhibitors (ICI)

被引：0
|
作者：
Xavier, Camila Braganca
Guardia, Gabriela
Lopes, Carlos Diego Holanda
Awni, Beatriz Mendes
Campos, Eduardo Felicio
Alves, Joao Pedro
Camargo, Anamaria Aranha
Galante, Pedro Alexandre Favoretto
Jardim, Denis L.
机构：
[1] Hosp Sirio Libanes, Sao Paulo, Brazil
[2] Falconi Consultants Results, Sao Paulo, Brazil
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2632
引用
收藏
页数：1
相关论文
共 44 条
  • [1] Interplay between mutational profile and TMB on overall survival: A post hoc analysis of 1,662 metastatic patients treated with immune checkpoint inhibitors
    Xavier, C. B.
    Lopes, C. D. H.
    Awni, B. M.
    de Campos, E. F.
    Alves, J. P. D. B.
    Jardim, D. L. F.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S1389 - S1389
  • [2] Identifying predictors of overall survival among TMB-low cancer patients treated with immune checkpoint inhibitors
    Xavier, C. B.
    Guardia, G.
    Alves, J. P.
    Lopes, C. D. H.
    Awni, B.
    de Campos, E. F.
    Camargo, A. A.
    Jardim, D. L. F.
    Galante, P.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S268 - S268
  • [3] Genomic evaluation of tumor mutational burden-high (TMB-H) versus TMB-low (TMB-L) metastatic breast cancer to reveal unique mutational features.
    Sammons, Sarah
    Elliott, Andrew
    Force, Jeremy Meyer
    DeVito, Nicholas C.
    Marcom, Paul Kelly
    Swain, Sandra M.
    Tan, Antoinette R.
    Torres, Evanthia T. Roussos
    Zeng, Jia
    Khasraw, Mustafa
    Balko, Justin M.
    Korn, Wolfgang Michael
    Anders, Carey K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [4] Tissue tumor mutational burden (TMB) as a biomarker of efficacy with immune checkpoint inhibitors (ICI) in metastatic gastrointestinal (mGI) cancers.
    Lentz, Robert William
    Friedrich, Tyler
    Hu, Junxiao
    Leal, Alexis Diane
    Kim, Sunnie S.
    Davis, S. Lindsey
    Purcell, Tom
    Messersmith, Wells A.
    Lieu, Christopher Hanyoung
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [5] Landscape of tumor mutational burden-high (TMB-high) and its correlation with immune checkpoint inhibitor biomarkers in gynecologic tumors
    Huang, Richard
    Lin, Douglas
    Danziger, Natalie
    Williams, Erik
    Elvin, Julia
    [J]. GYNECOLOGIC ONCOLOGY, 2021, 162 : S196 - S196
  • [6] Interplay between Tumor Mutational Burden and Mutational Profile and Its Effect on Overall Survival: A Pilot Study of Metastatic Patients Treated with Immune Checkpoint Inhibitors
    Xavier, Camila B.
    Lopes, Carlos Diego H.
    Awni, Beatriz M.
    Campos, Eduardo F.
    Alves, Joao Pedro B.
    Camargo, Anamaria A.
    Guardia, Gabriela D. A.
    Galante, Pedro A. F.
    Jardim, Denis L.
    [J]. CANCERS, 2022, 14 (21)
  • [7] Tumor mutational burden (TMB) in immune checkpoint inhibitor (ICI)-naive and -experienced patients with metastatic melanoma treated with lifileucel, a tumorinfiltrating lymphocyte (TIL) cell therapy.
    Kluger, Harriet M.
    Sarnaik, Amod
    Chesney, Jason Alan
    Lewis, Karl D.
    Weber, Jeffrey S.
    Gogas, Helen
    In, Gino Kim
    Terheyden, Patrick Andres Maximilian
    Lee, Sylvia
    Jagasia, Madan H.
    Masteller, Emma
    Qi, Rongsu
    Gontcharova, Viktoria
    Shi, Wen
    Fiaz, Rana
    Sulur, Giri
    Wu, Renee Xiao
    Chen, Guang
    Thomas, Sajeve Samuel
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [8] Role of tumor mutational burden (TMB) and microsatellite instability (MSI) in patients (pts) with advanced urothelial carcinoma (aUC) treated with immune checkpoint inhibitor (ICI)
    Bakaloudi, Dimitra Rafailia
    Talukder, Rafee
    Makrakis, Dimitrios
    Diamantopoulos, Leonidas Nikolaos
    Patgunarajah, Ubenthira
    Thomas, Vinay Mathew
    Jindal, Tanya
    Brown, Jason R.
    Miletic, Marija
    Johnson, Jeffrey
    Hui, Gavin
    Buznego, Lucia Alonso
    Morales-Barrera, Rafael
    Castaneda, David Humberto Marmolejo
    Nguyen, Charles B.
    Barata, Pedro C.
    Stewart, Tyler F.
    Gupta, Shilpa
    Grivas, Petros
    Khaki, Ali Raza
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 654 - 654
  • [9] Molecular differences between high and low tumor mutational burden (TMB) across breast cancer (BC) subtypes
    Licata, Luca
    Galbardi, Barbara
    Gyorffy, Balks
    Karn, Thomas
    Sica, Lorenzo
    Rognone, Alessia
    Zucchinelli, Patrizia
    Aldrighetti, Daniela
    Zambelli, Stefania
    Gianni, Luca
    Bianchini, Giampaolo
    [J]. CANCER RESEARCH, 2020, 80 (04)
  • [10] Association of biomarkers and response to immune checkpoint inhibitors (ICIs) in patients with metastatic urothelial carcinoma (mUC) with high and low tumor mutation burden (TMB).
    Jindal, Tanya
    Zhu, Xiaolin
    Zhang, Li
    Reyes, Kevin R.
    Deshmukh, Prianka
    de Kouchkovsky, Ivan
    Kumar, Vipul
    Maldonado, Edward
    Shipp, Chase
    Kwon, Daniel H.
    Borno, Hala
    Bose, Rohit
    Desai, Arpita
    Aggarwal, Rahul Raj
    Porten, Sima P.
    Small, Eric Jay
    Fong, Lawrence
    Chou, Jonathan
    Friedlander, Terence W.
    Koshkin, Vadim S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
12345